Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 27 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Empagliflozin and Linagliptin Tablets in two dosages. The production will take place at Zydus's manufacturing facility in Ahmedabad, and the tablets had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 27, 2025, titled "Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases